Large-scale manufacturing and characterization of CMV-CD19CAR T cells.
Xiuli WangRyan UrakMiriam WalterMin GuanTianxu HanVibhuti VyasSheng-Hsuan ChienBrenna GittinsMary C ClarkSally MokhtariAngelo CardosoDon J DiamondJohn ZaiaStephen J FormanRyotaro NakamuraPublished in: Journal for immunotherapy of cancer (2022)
We demonstrated the feasibility of our large-scale platform for generating CMV-CD19CAR T cells for clinical application. We plan to initiate a clinical trial at City of Hope using CMV-CD19CAR T cells for patients with intermediate/high-grade B cell non-Hodgkin's lymphoma immediately after autologous hematopoietic cell transplantation followed by vaccination with a novel CMV vaccine based on Modified Vaccinia Ankara (Triplex) 28 days and 56 days post-T cell infusion.